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A B S T R A C T
Purpose: In people with suspected inﬂammatory CNS disease, cerebrospinal ﬂuid (CSF) is commonly
analyzed. Antibody-associated limbic encephalitis (ab-LE) and anti-NMDAR-encephalitis are recognized
as two major syndromes of autoimmune epilepsies. Here, we investigated the diagnostic value of CSF
ﬁndings in these two entities.
Methods: We reviewed patients from our tertiary epilepsy centre with ab-LE and anti-NMDAR-
encephalitis in whom CSF examination including oligoclonal bands (OCB) was performed. Ab-LE patients
were subdivided according to antibodies (voltage-gated potassium channels, VGKC; glutamic acid
decarboxylase, GAD) or presence of onconeural antibodies/presence of tumour into three groups: VGKC-
LE, GAD-LE or paraneoplastic LE (PLE). As controls, patients with CSF investigations in whom
autoimmune origin was initially assumed but not conﬁrmed later on were included. In addition, a review
of published ab-LE and anti-NMDAR-encephalitis cases with reported CSF data was performed.
Results: 55 ab-LE (23 VGKC-LE, 25 GAD-LE, 7 PLE) and 14 anti-NMDAR-encephalitis patients were
identiﬁed at our centre. OCB were signiﬁcantly more frequent in ab-LE and anti-NMDAR-encephalitis
than in controls. Literature review identiﬁed 150 ab-LE and 95 NMDAR cases. Analysis of pooled data
conﬁrmed that presence of OCB was signiﬁcantly more frequent in ab-LE and anti-NMDAR-encephalitis
(especially in people with GAD-LE and anti-NMDAR encephalitis) as compared to controls. Sensitivity
and speciﬁcity of OCB in the pooled ab-LE and anti-NMDAR-encephalitis patients was 34% and 96%,
respectively. In patients with ab-LE and anti-NMDAR-encephalitis, the likelihood of OCB in CSF was 8.5-
fold higher as compared to controls. Furthermore, in the pooled ab-LE and anti-NMDAR-encephalitis
patients, cell counts in CSF were more frequently elevated (especially in those with anti-NMDAR
encephalitis) than in controls, whereas protein content of CSF was not different between the groups.
Conclusion: OCB, and to a lesser extent cell counts in CSF, appear to be helpful additional CSF markers in
the diagnostic evaluation of people presenting with a constellation suggestive for GAD-LE, PLE and anti-
NMDAR-encephalitis, prompting subsequent analysis of speciﬁc antibodies.
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There is increasing evidence that autoimmune-mediated mech-
anisms lead to epilepsy in a considerable proportion of patients.1
Antibody-associated limbic encephalitis (ab-LE) and anti-NMDAR-
encephalitis are the two major syndromes. Ab-LE is described as
paraneoplastic or non-paraneoplastic syndrome. Several non-
paraneoplastic subforms associated with serologically characterized
auto-antibodies (abs) were identiﬁed including those with abs
against voltage-gated potassium channels (VGKC) and glutamic
acid decarboxylase (GAD).1 Anti-NMDAR-encephalitis was ﬁrst* Corresponding author at: University of Bonn Medical Centre, Department of
Epileptology, Sigmund-Freud-Str. 25, 53105 Bonn, Germany. Tel.: +49 228 287
15712; fax: +49 228 287 19342.
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 2012 British Epilepsy Association. Published by Elsevier Ltd. Open access unddescribed as severe encephalopathic syndrome in young women
associated with a higher rate of ovarian teratoma,2 but it also occurs
in children, men and in people without teratomas.3
In general, these autoimmune-mediated epilepsies are rare and
multifaceted, and unfamiliar initial symptoms may hamper the
correct diagnosis at an early stage.4 In other neurological
conditions, analysis of cerebrospinal ﬂuid (CSF) is widely used
in routine neurological diagnostics to reveal constellations
suggestive for ongoing acute or chronic CNS inﬂammation.
Especially the selective presence of unmatched oligoclonal bands
(OCB) in CSF but not in serum is considered as a strong, although
unspeciﬁc marker of chronic CNS inﬂammation.5 Here, we asked
whether OCB and other CSF features are associated with ab-LE and
anti-NMDAR-encephalitis. To this end, we investigated all ab-LE
and anti-NMDAR-encephalitis patients at our centre and per-
formed a thorough review of published cases in literature with
regard to CSF ﬁndings.er CC BY-NC-ND license.
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2.1. Patient selection
All patients from our tertiary epilepsy centre in Bonn
with diagnosis of ab-LE and anti-NMDAR-encephalitis and
complete CSF investigations (see below) were retrospectively
included. In all these patients, we have routinely performed
3 Tesla brain MRI, routine EEG for 20 min or 24 h video-EEG
telemetry using scalp electrodes (10–20 system), neuropsycho-
logical testing, determination of known abs in serum and
CSF (also in order to exclude encephalitis due to infectious
agents).
Ab-LE and anti-NMDAR-encephalitis was deﬁned by new-onset
epilepsy (seizure onset not longer than 5 years prior to ﬁrst
assessment at our centre independently of seizure frequency and
whether seizures were the sole or predominant clinical symptom)
and the presence of abs in serum or CSF. According to additional
clinical symptoms and speciﬁc antibodies, the following two
syndromes were distinguished:
1. Ab-LE: Patients with ‘‘limbic’’ signs and symptoms (1 of the
following: seizures of temporal lobe semiology, disturbance of
episodic memory, affective disturbances), brain MRI revealing
mesiotemporal encephalitis (T2/FLAIR hyperintensity without
atrophy) and presence of speciﬁc abs and/or identiﬁcation of a
tumour.1,6 In all patients serum was tested for presence of the
following abs: VGKC, GAD, onconeural abs, N-methyl-D-aspar-
tate-receptor (NMDAR).
2. Anti-NMDA-encephalitis: Patients were assessed according to
described clinical features and identiﬁcation of NMDAR-abs.2
As controls, we included all patients who have undergone CSF
investigations for initial suspicion of autoimmune origin which
has not been conﬁrmed later on. The diagnosis of non-
autoimmune epilepsy was based on the absence of known
abs, absence of typical MRI ﬁndings (e.g. initial swelling of
mesiotemporal structures and subsequent remission or devel-
opment of atrophy) and the presence of other plausible
aetiology for epilepsy.
2.2. Review of the literature
We performed a systematic review of the literature using the
following search terms: limbic encephalitis, limbic encephalitis
VGKC, limbic encephalitis GAD, anti-NMDAR-encephalitis. Limits
were deﬁned as: published in the last 10 years, only items with
link to full text, humans, type of article (Clinical Trial,
Randomized Controlled Trial, Case reports, Classical article,Table 1
CSF features of ab-LE and anti-NMDAR-encephalitis in the Bonn patients.
Bonn patients Elevated cell
counts (>5/ml)
Elevated prote
content (>500
All (N = 69) 11 16 
Ab-LE all (N = 55) 9 11 
VGKC-LE (N = 23) 3 6 
GAD-LE (N = 25) 3 2 
PLE (N = 7) 3 3 
NMDAR (N = 14) 2 5 
Non-autoimmune controls (N = 28) 1 8 
p-Values (all vs. controls) 0.17a 0.61a
p-Values (ab-LE vs. controls) 0.15a 0.42a
p-Values (NMDAR vs. controls) 0.25a 0.73a
Ab-LE: antibody associated limbic encephalitis; VGKC: antibodies to VGKC; GAD: antibo
CSF/serum-quotient according to Reiber5; OCB: unmatched oligoclonal bands in CSF, n
a Fisher exact test, signiﬁcances after Holm–Bonferroni corrections are highlighted iJournal Article), subsets MEDLINE, language English. All previous
publications from our institution in Bonn were excluded to avoid
data interferences. Only publications with data of CSF with OCB
determination and clearly assigned to individual patients were
included in further analysis.
2.3. Comparison of patient cohorts
First, CSF data of the ab-LE and anti-NMDAR-encephalitis
patients of our centre were compared to our control group (see
Section 2.6). Second, we have pooled all CSF data (including our
own patients and the published cases) and compared these pooled
data to our local controls. Individual CSF data were not reported in
all of the published patients. In those cases missing data were
excluded from analysis.
2.4. CSF analysis
All data were obtained in clinical routine diagnostics.
Complete CSF analysis included cell count, protein content,
and evaluation of blood-CSF-barrier function, intrathecal IgG
synthesis by Reiber-scheme and by OCB. White cell counts >5/
ml without erythrocytosis and CSF protein >500 mg/l were
deﬁned as abnormally elevated. As internationally accepted
parameter for blood-CSF function age-dependent albumin-CSF/
serum-quotient QAlb was used.
5 Intrathecal IgG synthesis as an
indicator for humoral immune response was assessed quantita-
tively by IgG-CSF/serum-quotient QIgG (values >0.7 indicating
for intrathecal synthesis)5 and qualitatively by OCB in isoelectric
focusing (IEF) according to international consensus.7 Unmatched
OCBs in CSF and not in serum were considered as markers for
autochthone intrathecal IgG production. If available, repeated
CSF investigations in patients were considered in the same
manner.
2.5. Ab determination
Ab testing was performed as follows: Serum VGKC-abs were
assessed by radioimmunoprecipitation assay (RIA; normal values
<100 pmol/l, AV, Weatherall Institute, Oxford, UK and EURO-
IMMUN laboratory, Luebeck, Germany).8 Identiﬁcation of GAD-
abs in serum was performed by RIA using 125I-GAD (normal
values 1 U/ml, AV)6 or by indirect immunoﬂuorescence (IFT,
nomal values <1:10, EUROIMMUN). ‘‘Well characterized’’ onco-
neural abs were also tested by a commercially available routine
test using an immune-dot-blot for Hu, Ma, amphiphysin, CV2/
CRMP5 abs (Ravo Diagnostika, Freiburg, Germany). NMDAR-abs
were tested by speciﬁc immunoﬂuorescence test (IFT, AV and
EUROIMMUN).9in
 mg/l)
Blood-CSF-
disturbance
Intrathecal IgG
synthesis (QIgG)
Intrathecal IgG
synthesis (OCB)
19 2 25
14 2 18
8 1 0
4 1 14
2 0 4
5 0 7
9 0 1
0.81a 1a <0.001a
0.61a 0.55a 0.002a
1a 1a <0.001a
dies to GAD; PLE: paraneoplastic LE; NMDAR: anti-NMDAR-encephalitis; QIgG: IgG-
ot in serum.
n bold.
Table 2
Clinical characteristics of patients with ab-LE and anti-NMDAR-encephalitis in Bonn.
Bonn patients Gender Median age at onset in years (range) Median disease duration in months (range)
All (N = 69) 41 , 38 (8–73) 10 (0–252)
Ab-LE all (N = 55) 28 , 43 (8–73) 10 (0.3–252)
VGKC-LE (N = 23) 7 , 57 (20–73) 7 (0.3–23)
GAD-LE (N = 25) 16 , 25 (8–65) 40 (1–252)
PLE (N = 7) 5 , 47 (14–60) 34 (0.4–71)
Anti-NMDAR-Enzephalitis (N = 14) 13 , 25 (17–58) 16 (0–168)
Non-autoimmune controls (N = 28) 16 , 41 (16–73) 13 (0.6–116)
For abbreviations see legend in Table 1.
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For nominal data, Fisher’s exact test was used. Due to multiple
comparisons, p-values were adjusted according to the Holm–
Bonferroni stepwise correction procedure, p-value <0.05 were
considered signiﬁcant. Sensitivity and speciﬁcity were calculated
according to gold-standard test. For assessing the value of
performed diagnostic tests, the likelihood ratio was calculated
with values >1 indicating positive association with disease.
3. Results
3.1. Patient characteristics
A total of 69 patients with ab-LE and anti-NMDAR-encephalitis
were identiﬁed in Bonn: 55 ab-LE and 14 anti-NMDAR encephalitis
patients. Ab-LE patients were subclassiﬁed according to ab
identiﬁcation (VGKC-LE, GAD-LE) or onconeuronal abs and
detected tumour (paraneoplastic LE, PLE; two patients had
onconeuronal ab without detected tumour), for distribution and
clinical patient details, see Tables 1 and 2. Twenty-eight control
patients were included. They were ﬁnally diagnosed as having
psychogenic non-epileptic seizures (N = 7), syncope (N = 5),
structural epilepsies of other origin than auto-immune mediated
mechanisms (N = 6: 2 tumour, 1 infarction, 1 severe head trauma, 2
dysplasia), psychiatric disorders (N = 5: 2 depression, 1 anxiety, 1
psychosis, 1 obsessive–compulsive disorder), dementia (N = 3) or
with other conditions (N = 2: 1 transitory ischaemic attacks, 1
normal pressure hydrocephalus) or no identiﬁed disease (N = 1).
The patient positive for OCB was a 68-year-old woman with a new-
onset structural epilepsy due to infarction.
3.2. Review of the literature
Four hundred and ﬁfty-seven articles matched searching
criteria, 58 studies matched inclusion criteria: 36 dealt with ab-
LE (VGKC: 12; GAD: 8: onconeural: 13; various: 3) and 22 focused
on anti-NMDAR-encephalitis. In a total of 245 reported ab-LE andTable 3
CSF features of ab-LE and anti-NMDAR-encephalitis in the pooled Bonn and published
Pooled data Elevated cell
counts (>5/ml)
All (N = 314) 123/304 
Ab-LE all (N = 205) 44/197 
VGKC-LE (N = 109) 23/106 
GAD-LE (N = 49) 3/48 
PLE (N = 40) 18/36 
Others (N = 7) 0/7 
Anti-NMDAR-Enzephalitis (N = 109) 79/107 
Non-autoimmune Bonn controls (N = 28) 1/28 
p-Values (all vs. controls) <0.0001 
p-Values (ab-LE vs. controls) 0.02 
p-Values (NMDAR vs. controls) <0.0001 
For abbreviations see legend in Table 1.anti-NMDAR-encephalitis patients, CSF data were individually
assigned as follows: 150 ab-LE patients (86 VGKC, 24 GAD, 33 PLE,
7 with combination of abs) and 95 NMDAR patients. Details and
references of literature are given in Supplementary Table 1.
3.3. CSF ﬁndings
3.3.1. Bonn patients
CSF ﬁndings are highlighted in Table 1. Only intrathecal IgG
synthesis ascertained by OCB was different between the patient
groups: it was more frequent in ab-LE and anti-NMDAR-
encephalitis patients than in controls (p < 0.001) even when
comparing separately anti-NMDAR-encephalitis (p < 0.001) and
LE (p = 0.002). Notably, consideration of ab-LE-subforms revealed
that presence of OCB in VGKC-LE was not different to controls,
whereas OCB was signiﬁcantly associated with GAD-LE and PLE
(VGKC vs. controls p = 1; GAD p < 0.001; PLE p = 0.003). Sensitivity
for OCB amounted only to 36% in the Bonn patients with ab-LE and
anti-NMDAR-encephalitis (ab-LE: 33%; NMDAR: 50%), whereas
speciﬁcity amounted to 96%. The likelihood for OCB in people with
ab-LE and anti-NMDAR-encephalitis was 9-fold higher as com-
pared to controls (likelihood ratio; ab-LE: 8.25, NMDAR: 12.5).
Serial CSF investigations were performed in 29 (42%) ab-LE and
anti-NMDAR-encephalitis patients (19 ab-LE, 10 NMDAR) over a
median period of 15 months (range 1–84), but not in the control
group. OCB were positive in 13 of these patients (43%).
Interestingly, in those patients in whom OCB was not detected
in the ﬁrst CSF examination, OCB was not revealed in the further
course (see Supplementary Table 2).
3.3.2. Pooled data of published cases and patients from Bonn
In published ab-LE and anti-NMDAR-encephalitis patients
(N = 245), elevated cell counts were reported in 112/235 (48%)
patients and elevated protein counts in 73/229 (32%) patients. OCB
were reported in CSF of 82/199 (41%) ab-LE and anti-NMDAR-
encephalitis patients: in 35/136 (26%) published ab-LE patients (8/
77 VGKC, 13/23 GAD, 14/29 PLE) and in 47/63 (75%) published
NMDAR patients. patients.
Elevated protein
content (>500 mg/l)
Intrathecal IgG
synthesis (OCB)
89/298 107/268
59/197 53/191
37/106 8/100
5/48 27/48
15/36 18/36
2/7 0/7
30/101 54/77
8/28 1/28
1 <0.0001
1 0.004
1 <0.0001
Table 4B
Sensitivity, speciﬁcity and likelihood ratio of elevated cell counts in CSF for the
pooled data (our centre and published patients).
Pooled data
Elevated cell counts
Sensitivity % Speciﬁcity % Likelihood ratio
All vs. controls 40 96 10
Ab-LE vs. controls 22 96 5.5
VGKC 22 96 5.5
GAD 6 96 1.5
PLE 50 96 12.5
NMDAR vs. controls 74 96 18.5
For abbreviations see legend in Table 1.
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cases and compared to our controls (Table 3). Again, presence of OCB
was more frequently detected in ab-LE and anti-NMDAR-encepha-
litis (p < 0.001), and more speciﬁcally in the subgroup of anti-
NMDAR-encephalitis (p < 0.001) as compared to controls. Further-
more, cell counts were elevated more frequently in ab-LE and anti-
NMDAR-encephalitis patients (p < 0.001) than in controls, especial-
ly in patients with anti-NMDAR-encephalitis (p < 0.001) but not in
patients with ab-LE when compared separately.
Values of sensitivity, speciﬁcity and likelihood ratios for OCB
and for elevated cell counts in CSF are given for the pooled Bonn/
published ab-LE and anti-NMDAR-encephalitis patients in Tables
4A and 4B.
4. Discussion
We have found that (i) OCB are more frequently observed in
people with ab-LE and anti-NMDAR-encephalitis, particularly in
people with GAD-LE and anti-NMDAR encephalitis, and that (ii)
abnormally elevated cell counts are associated with anti-NMDAR
encephalitis. Thus, CSF ﬁndings may be a useful marker in the
diagnostic evaluation of people in whom autoimmune-mediated
epilepsy is suspected, prompting further examinations including
detailed search for antibodies typically associated with subforms
of autoimmune-mediated epilepsies.
Due to the retrospective design, however, our study has several
limitations. First, our clinic is a tertiary reference centre for people
with chronic epilepsy, and our data is thus biased by the presence of
recurrent seizures. People with autoimmune-mediated processes
without seizures or people with seizures due to viral or bacterial
encephalitis were not considered. Second, because of diagnostic
uncertainties and lacking diagnostic ‘‘gold-standard’’, people in
whom autoimmune-mediated epilepsy was suspected, but in whom
known abs (see methods) were not detected, were excluded from the
study. Third, we have selectively included patients in whom CSF and
OCB investigations have been performed based on clinical judge-
ment. Therefore, our study is biased for patients with CSF samples
and initial assumption of CNS inﬂammation. For clinical purpose, it
would be of outstanding interest to know the predictive positive and
negative values of CSF ﬁndings for ab-LE and anti-NMDAR-
encephalitis. This is, however, not possible, as we cannot reliably
estimate the prevalence of ab-LE and anti-NMDAR-encephalitis.
Despite these limitations, our study provides extensive data
(including literature review) on the usefulness of CSF ﬁndings in a
clinically well characterized population including a variety of
autoimmune-mediated epilepsy syndromes. We have found that
OCB are more frequently observed in people with ab-LE and anti-
NMDAR-encephalitis with a likelihood of 8.5-fold higher as
compared to controls, suggesting that especially OCB are a useful
supportive marker in the diagnostic evaluation of autoimmune-
mediated epilepsies. Importantly, when OCB are negative at ﬁrst
CSF examination, the probability of OCB detection in the further
course in serial lumbar punctures is low. Whereas speciﬁcity isTable 4A
Sensitivity, speciﬁcity and likelihood ratio of OCB for the pooled data (our centre
and published patients).
Pooled data
OCB
Sensitivity % Speciﬁcity % Likelihood ratio
All vs. controls 34 96 8.5
Ab-LE vs. controls 28 96 7
VGKC 7 96 1.75
GAD 59 96 14.75
PLE 50 96 12.5
NMDAR vs. controls 67 96 16.75
For abbreviations see legend in Table 1.relatively high, sensitivity for OCB in ab-LE and anti-NMDAR-
encephalitis was low. Based on these results, negative OCB do of
course not exclude autoimmune aetiology such as ab-LE and anti-
NMDAR-encephalitis and further investigations such as ab testing
and tumour search are required. In this context, it is important to
note that we have not included people with suspected limbic
encephalitis without detection of known abs in this study, as an
international consensus on the ‘‘gold-standard’’ of diagnostic
work-up has not been reached yet. Thus, there might also be
patients with autoimmune-mediated epilepsies without detected
abs, but abnormal CSF ﬁndings.
Whereas pathological CSF ﬁndings were described frequently in
‘‘classic’’ paraneoplastic LE,10 knowledge about their occurrence in
the recently identiﬁed non-paraneoplastic ab-positive subforms is
scarce. In people with VGKC-LE only slight increases of protein
levels and cell counts in CSF were reported11 whereas OCB were
found in 60% of patients with anti-NMDAR-encephalitis.3 In line
with these reports, none of our patients and only 11% of the
published VKGC-LE cases had OCB.
The presence of OCB as a measure of intrathecal ab synthesis in
anti-NMDAR encephalitis and GAD-LE suggests that these entities
may depend on a primary pathological process within the brain or,
alternatively, that they develop after migration of ab-producing
cells into the CNS.1 In contrast, the absence of OCB (and abs within
the CSF, as shown by others1,11) in people with VGKC-LE is in
favour of a primary peripheral synthesis outside of the central
nervous system and subsequent diffusion across the blood-CSF
barrier where the abs secondarily lead to neuronal hyperexcitabil-
ity and maybe inﬂammation.1,12 This is, however, pure speculation
and further neuropathological examinations of brain tissue in
affected patients as well as experimental laboratory investigations
are required to address these questions.
5. Conclusion
Our data suggest that CSF investigations with determination of
OCB are a supportive marker if autoimmune-mediated epilepsies
such as GAD-LE, PLE and anti-NMDAR-encephalitis are suspected,
whereas it failed to provide signiﬁcance in VGKC-LE. Ab testings
and tumour search should be undertaken to specify the underlying
syndrome.
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